The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II study of pembrolizumab in combination with radiation with or without olaparib in localized high-risk prostate cancer.
 
Zin Myint
Research Funding - Merck (Inst)
 
William H St. Clair
No Relationships to Disclose
 
Stephen Strup
No Relationships to Disclose
 
Patrick J. Hensley
No Relationships to Disclose
 
Donglin Yan
No Relationships to Disclose
 
Jonathan David Tward
Honoraria - Bayer
Consulting or Advisory Role - Bayer; Bayer; Blue Earth Diagnostics; Boston Scientific; Boston Scientific; Janssen Scientific Affairs; Lantheus Medical Imaging; Merck; Myovant Sciences; Myriad Genetics; Myriad Genetics; Myriad Genetics
Research Funding - Bayer (Inst); Myriad Genetics (Inst)
Expert Testimony - Expert Consulting Services
Travel, Accommodations, Expenses - Bayer; Myriad Genetics
 
Benjamin L. Maughan
Consulting or Advisory Role - Astellas Medivation; AVEO; Bavarian Nordic; Bayer; Bristol-Myers Squibb; Clovis Oncology; Exelixis; Janssen Oncology; Merck; Peloton Therapeutics; Pfizer; Tempus
Research Funding - Bavarian Nordic (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Exelixis (Inst)
Travel, Accommodations, Expenses - Exelixis